CRENESSITY dosing varies by age and weight1
| Age and body weight | Recommended dosage |
|---|---|
| Adults (18 and older) and children weighing ≥55 kg | Capsules: 100 mg twice daily (200 mg per day) |
| Children weighing 20 to <55 kg | Capsules or oral solution: 50 mg twice daily (100 mg per day) |
| Children weighing 10 to <20 kg | Oral solution: 25 mg twice daily (50 mg per day) |
CRENESSITY is a CYP3A4 substrate¹
- CRENESSITY when coadministered with a strong or moderate CYP3A4 inducer1
- Please refer to the full Prescribing Information for full dosing information and additional considerations for patients taking CYP3A4 inducers or inhibitors
CRENESSITY does not address cortisol deficiency. Patients prescribed CRENESSITY should continue taking GCs.1,2
CRENESSITY should be used alongside GC therapy and has no contraindications with any specific GC used in the treatment of CAH.
Around-the-clock ACTH and androgen reduction
When comparing doses, twice-daily dosing led to the greatest reduction of androstenedione.3*
*A phase 2 study compared 50 mg once daily, 100 mg once daily, and 100 mg twice daily. Main outcomes included change from baseline to day 14 in ACTH, 17-OHP, androstenedione, and testosterone. 100 mg twice daily led to the greatest reductions.3
A pharmacokinetic profile that
supports twice-daily dosing1
Following oral administration, the time to reach maximum CRENESSITY plasma concentration is
4 hours1
The effective half-life of
CRENESSITY is approximately
14 hours1
CRENESSITY administration
- CRENESSITY should be taken twice a day1
CRENESSITY should be taken in the morning and evening. CRENESSITY dosing can be timed with GC doses.
- CRENESSITY must be taken with a meal1,4
CRENESSITY works best when taken with food containing at least 5 g of fat. Instruct patients to take CRENESSITY with foods like:
- A glass of whole, 2%, or chocolate milk (not skim)
- A glass of full-fat oat milk
- Crackers with cheese or peanut butter
- A granola bar with nuts
- Half an avocado
- An apple with peanut
butter
- CRENESSITY is available as capsules and as an oral solution1
Capsules should be swallowed whole with liquid and not opened, chewed, or broken. Oral solution should not be diluted and should be taken with an oral syringe.
of pediatric patients rated the oral solution as easy or very easy to take (n=35).5
Patients aged 6-17 years rated ease of administration on a 5-option scale ranging from very difficult to very easy.5
Support your patients taking CRENESSITY through GC down‑titration
Tailor the process to each patient’s clinical picture6
When reducing GCs, preparation and communication are key. Patients may experience withdrawal symptoms—especially with faster reductions—but these symptoms typically improve within a few weeks to a month. Setting expectations early can help maintain adherence to both CRENESSITY and the broader treatment plan. Discuss common symptoms of GC withdrawal.6
Patients prescribed CRENESSITY should continue taking GCs.1
GC Down-Titration
Explore GC reduction strategies, key clinical considerations, and the importance of ongoing patient monitoring.
Consider mineralocorticoid support during GC down-titration
Some GCs—especially hydrocortisone—have mineralocorticoid effects. As GC doses are lowered, mineralocorticoid activity may also decrease. This can increase the need for fludrocortisone supplementation.7
To guide mineralocorticoid adjustments, monitor8,9:
- Plasma renin levels
- Blood pressure
- Electrolyte levels
Every patient’s experience is different. Encourage ongoing dialogue as you adjust GC dosing alongside CRENESSITY treatment.6
GC OPTIMIZE™ calculator
Powered by expert recommendations, GC OPTIMIZE™ can help guide dose reductions when managing patients with classic CAH who are taking CRENESSITY for androgen control.
Develop a personalized GC dose reduction strategy at each visit using current GC doses, lab results, and your patient’s treatment goals.
As patients vary in clinical presentation, this calculator may not be appropriate for every person with classic CAH. Adjustments to GC doses should be individualized based on each patient's clinical needs and the clinician's experience.
Body Surface Area Calculator
When making changes to your patient’s GC regimen, the Body Surface Area Calculator can help determine your patient’s new GC dose. Simply input their height and weight to get the results.
GC Conversion Calculator
When considering switching your patient from one type of GC to another, the GC Conversion Calculator can help you determine the equivalent dose.
ACCESS SIMPLIFIED
Dedicated team of Care Coordinators
The Neurocrine Access Support program provides patients a dedicated Care Coordinator as a central point of contact from initiation through their entire treatment journey.
Discover Access Support
REFERENCES